Jan Krönke

21PUBLICATIONS
88CO-AUTHORS
Gene and molecular therapyMedical mycologyCatalysis and mechanisms of reactionsMedical molecular engineering of nucleic acids and proteinsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 06, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|Jun 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|Feb 17, 2026
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

C Riedhammer, M Truger, H Lee

|Dec 18, 2025
The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma.

Kaiting Jiang, Marieluise Kirchner, Frederik Herzberg

|Dec 16, 2025
A Facile Protocol for C(sp2)-C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands.

Anita Maksutova, Thomas M Geiger, Lorenzo Cianni

|Nov 26, 2025
The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma.

Kaiting Jiang, Marieluise Kirchner, Frederik Herzberg

Pageof 4

Frequent Collaborators

6 joint publications

Ulrich Keller

5 joint publications

Hermann Einsele

5 joint publications

K Martin Kortüm

5 joint publications

Christian Steinebach